About InVivoSIM anti-human CD20 (Ofatumumab Biosimilar) This non‑therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Ofatumumab, making it ideal for research use. Ofatumumab is a fully human IgG1 monoclonal antibody that specifically targets CD20, a B cell surface antigen expressed from the pre‑B to mature B cell stage but not on plasma cells. CD20 plays a critical role in B cell development, activation, and proliferation. By binding to a unique membrane‑proximal epitope on CD20, Ofatumumab induces B cell depletion through complement‑dependent cytotoxicity (CDC) and antibody‑dependent cellular cytotoxicity (ADCC). This Ofatumumab biosimilar is well suited for studying B cell–mediated diseases, CD20 biology, and the immunologic mechanisms of B cell depletion in autoimmune disease and cancer. InVivoSIM anti-human CD20 (Ofatumumab Biosimilar) Specifications IsotypeHuman IgG1, κ Recommended Isotype Control(s)RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman CD20 Reported ApplicationsIn vivo functional assays in vitro functional assays Flow cytometry ELISA FormulationpH 7.0 Contains no stabilizers or preservatives Endotoxin≤0.5EU/mg (≤0.0005EU/μg)Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity≥95%Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
